Neogenomics (NEO) Operating Income: 2009-2025
Historic Operating Income for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -$27.0 million.
- Neogenomics' Operating Income fell 27.44% to -$27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$120.9 million, marking a year-over-year decrease of 30.98%. This contributed to the annual value of -$92.1 million for FY2024, which is 14.51% up from last year.
- Latest data reveals that Neogenomics reported Operating Income of -$27.0 million as of Q3 2025, which was up 43.28% from -$47.6 million recorded in Q2 2025.
- In the past 5 years, Neogenomics' Operating Income ranged from a high of -$15.1 million in Q1 2021 and a low of -$52.0 million during Q1 2022.
- In the last 3 years, Neogenomics' Operating Income had a median value of -$27.0 million in 2025 and averaged -$27.5 million.
- In the last 5 years, Neogenomics' Operating Income plummeted by 950.57% in 2021 and then spiked by 38.76% in 2023.
- Neogenomics' Operating Income (Quarterly) stood at -$41.6 million in 2021, then spiked by 36.53% to -$26.4 million in 2022, then grew by 29.60% to -$18.6 million in 2023, then grew by 0.93% to -$18.4 million in 2024, then fell by 27.44% to -$27.0 million in 2025.
- Its last three reported values are -$27.0 million in Q3 2025, -$47.6 million for Q2 2025, and -$27.8 million during Q1 2025.